DOM-CIPROFLOXACIN TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
10-09-2019
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)
제공처:
DOMINION PHARMACAL
ATC 코드:
J01MA02
INN (International Name):
CIPROFLOXACIN
복용량:
100MG
약제 형태:
TABLET
구성:
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 100MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
QUINOLONES
제품 요약:
Active ingredient group (AIG) number: 0123207005; AHFS:
승인 상태:
APPROVED
승인 날짜:
2004-03-24
제품 특성 요약
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DOM-CIPROFLOXACIN
(Ciprofloxacin Hydrochloride Tablets, USP)
100 mg, 250 mg, 500 mg and 750 mg
ANTIBACTERIAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Quebec
H4P 2T4 DATE OF REVISION: SEPTEMBER 10, 2019
SUBMISSION CONTROL NO.: 229111
_Dom-CIPROFLOXACIN Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
6
WARNINGS AND PRECAUTIONS
............................................................................................
6
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
19
OVERDOSAGE
...........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
21
STORAGE AND STABILITY
....................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................
전체 문서 읽기
